Extended Use of MAO-B Inhibitors Slows Decline in Parkinson's Disease Patients

(IOS Press) There has long been interest in whether monoamine oxidase type B (MAO-B) inhibitors slow progression of Parkinson's disease (PD) and improve long-term outcomes. They have shown neuroprotective effects in cell culture and animal studies of PD, but clinical trial results have been mixed and have failed to convincingly demonstrate disease modifying effects in people with PD.